

In the Claims

Please amend the claims as follows. Applicant has included herewith a complete claim set with insertions and deletions indicated by underlining and strikethrough (or double bracketing), respectively.

1. (Currently amended) A therapeutic vehicle adapted for application to acute or chronic cutaneous wounds wherein said vehicle has integral therewith, or applied thereto, a cell culture surface obtainable by plasma polymerisation and containing a carboxylic acid functionality of at least 5%, to which at least one keratinocyte is attached, ~~to which cells comprising keratinocytes attach and detach to transfer to a wound bed of the acute or chronic cutaneous wounds,~~ characterised in that said at least one keratinocyte is capable of detachment from said culture surface and transfer to an acute or chronic cutaneous wound, upon contact with a wound bed ~~the surface contains a carboxylic acid functionality of at least 5%.~~
2. (Original) A vehicle according to claim 1, wherein said surface acid functionality is between 5-20%.
3. (Previously presented) A vehicle according to claim 1, wherein said surface acid functionality is greater than 20%.
4. (Canceled)
5. (Previously presented) A vehicle according to claim 1, wherein said carboxylic acid functionality is provided by propionic acid.
6. (Previously presented) A vehicle according to claim 1, wherein said carboxylic acid functionality is provided by acrylic acid.
7. (Previously presented) A vehicle according to claim 1, wherein said surface is provided by coating a substrate with a plasma co-polymer of a carboxylic acid containing monomer.

8. (Original) A vehicle according to claim 7, wherein said co-polymer is a mixture of acrylic acid and a hydrocarbon.
9. (Original) A vehicle according to claim 8, wherein said hydrocarbon is 1,7-octadiene.
10. (Original) A vehicle according to claim 9, wherein acrylic acid is provided at 50-100% and 1,7-octadiene is provided at 0-50% in the gas feed.
11. (Previously presented) A vehicle according to claim 1, wherein said surface is suitable for use with cells of mammalian origin.
12. (Original) A vehicle according to claim 11 wherein said mammalian cells are human.
- 13.-14. (Canceled)
15. (Previously presented) A vehicle according to claim 1, wherein said vehicle comprises matrix material.
- 16-24. (Canceled)
25. (Previously presented) A method for the treatment of cutaneous wounds, comprising using a therapeutic vehicle according to claim 1.
26. (Original) A method according to claim 25, wherein said plasma is created using a plasma power of 0-50W and a flow rate of 0-20sccm under continuous wave conditions.
27. (Original) A method according to claim 25, wherein said plasma is created using pulsed wave conditions.

28. (Previously presented) A method for the treatment of acute or chronic cutaneous wounds, comprising using a therapeutic vehicle according to claim 8, wherein said acid is acrylic acid and said hydrocarbon is 1,7-octadiene.

29. (Original) A method according to claim 28, wherein said plasma comprises 50-100% acrylic acid and 0-50% 1,7-octadiene in the gas feed.

30. (Previously presented) A method according to claim 29, wherein said plasma comprises the following percentages of acrylic acid and 1,7-octadiene:

acrylic acid %	1,7-octadiene %
50	50
60	40
70	30
80	20
90	10
100	0

31. (Previously presented) A method according to claim 29, wherein said plasma comprises the following percentages of acid and hydrocarbon:

acid %	hydrocarbon %
50	50
60	40
70	30
80	20
90	10
100	0

32. (Previously presented) A therapeutic vehicle according to claim 1, wherein said vehicle is a prosthesis, an implant, a matrix, a stent, a gauze, a bandage, a plaster, a biodegradable matrix or a polymeric film.